(Q33669018)

28 July 2017

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma (English)

1 reference

28 July 2017

1 reference

Rachel Hamelers

14

0 references

Debra M Sarasohn

Debra Sarasohn

9

0 references

Paul Hamlin

Paul Hamlin

4

0 references

Andrew D Zelenetz

Andrew D Zelenetz

6

0 references

Owen A O'Connor

16

Owen A O'Connor

1 reference

28 July 2017

John Gerecitano

1

1 reference

28 July 2017

Carol Portlock

2

1 reference

28 July 2017

Craig Moskowitz

3

1 reference

28 July 2017

David Straus

5

1 reference

28 July 2017

Zhigang Zhang

7

1 reference

28 July 2017

Otilia Dumitrescu

8

1 reference

28 July 2017

Dorothy Lin

10

1 reference

28 July 2017

Jennifer Pappanicholaou

11

1 reference

28 July 2017

Barbara M Cortelli

12

1 reference

28 July 2017

Ellen Neylon

13

1 reference

28 July 2017

John Wright

15

1 reference

28 July 2017

language of work or name

English

0 references

publication date

16 July 2009

1 reference

British Journal of Haematology

28 July 2017

1 reference

28 July 2017

146

1 reference

28 July 2017

652-655

1 reference

28 July 2017

6

1 reference

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4035037

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4035037

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4035037

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4035037

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4035037

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4035037

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4035037

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4035037

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4035037

Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4035037

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4035037

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19624539

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2141.2009.07775.X

1 reference

28 July 2017

1 reference

28 July 2017

1 reference